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Most disorders are caused by a combination of multiple genetic and/or environmental factors. If
two diseases are caused by the same molecular mechanism, they tend to co-occur in patients. Here
we provide a quantitative method to disentangle how much genetic or environmental risk factors
contribute to the pathogenesis of 358 individual diseases, respectively. We pool data on genetic,
pathway-based, and toxicogenomic disease-causing mechanisms with disease co-occurrence data ob-
tained from almost two million patients. From this data we construct a multilayer network where
nodes represent disorders that are connected by links that either represent phenotypic comorbidity of
the patients or the involvement of a certain molecular mechanism. From the similarity of phenotypic
and mechanism-based networks for each disorder we derive measure that allows us to quantify the
relative importance of various molecular mechanisms for a given disease. We find that most diseases
are dominated by genetic risk factors, while environmental influences prevail for disorders such as
depressions, cancers, or dermatitis. Almost never we find that more than one type of mechanisms
is involved in the pathogenesis of diseases.
I. INTRODUCTION
Multifactorial diseases are disorders that involve multi-
ple disease-causing mechanisms, such as genes acting in
concert with environmental factors. The represent one
of the most significant challenges that medical research
faces today [1]. Disease-causing mechanisms may be (and
typically are) involved in more than one disorder [2]. If
two diseases are related to the same mechanism (say, a
single point mutation, SNP, or an altered metabolic path-
way), they have a tendency to co-occur in the same pa-
tients [3, 4]. Here we develop a novel network-medicine
approach to quantify the relative contributions of genetic
and environmental risk factors for diseases. The central
idea of the approach is illustrated in figure 1. We consider
three diseases i, j, k (circles) and assume that diseases
i and j co-occur very frequently in patients (thick line),
whereas diseases i and k rarely coincide within patients
(thin line). Assume further that i can arise through two
different disease-causing mechanisms, A and B, where
mechanism A is also responsible for (or involved in) dis-
ease k and mechanism B for disease j. Obviously, mech-
anism B explains the observed disease phenotype i (the
frequent co-occurrence with disease j) much better than
mechanism A and is therefore a more probable causes for
disease i. Using this idea we are able to identify the most
likely causes and are able to disentangle genetic and en-
vironmental disease-causing mechanisms for 358 different
disease phenotypes.
We consider the three most important classes of
disease-causing mechanisms. (i) Genetic mechanisms re-
late a disease to a specific defect or alteration in the
genome. If one such defect is related to two or more
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FIG. 1: Consider three diseases i, j, k (blue circles) and as-
sume that disease i co-occurs very frequently with j (thick
line) but only in rare cases with k (thin line). Further, as-
sume that there are two different disease-causing mechanisms
for i, A and B, where mechanism A (B) is also known to
be involved in disease k (j). Since i is very often observed
together with j, but not with k, mechanism B explains the
disease phenotype i much better than A.
pathologies, then those diseases share a genetic comor-
bidity. For example, it was shown that the phenotypic
comorbidity between schizophrenia and Parkinson’s dis-
ease is almost entirely accounted for by SNPs in loci near
NT5C2 and HLA-DRA [5]. (ii) Pathway-based mecha-
nisms are given by a defective pathway (e.g. metabolic
or signal transduction pathway) that is involved in the
etiology of the disease. Pathway-based comorbidities in-
dicate that two diseases are related to different defects
in the same pathway. For instance, it is known that the
Pi3K/AKT pathway up-regulates anti-inflammatory cy-
tokines and inhibits proinflammatory cytokines such as
2IL-1b, IL-6, TNF-α, and IFN-γ that show increased lev-
els in patients with major depressive disorder [6]. Also,
inactivation of the Pi3K/AKT pathway through the sup-
pression of insulin receptor substrates (IRS) may act as
the underlying mechanism for the metabolic syndrome
(i.e. the frequent concurrence of metabolic disorders such
as hypertension, obesity, or diabetes) [7]. Indeed, depres-
sion has been identified as an important comorbidity of
the metabolic syndrome in various cross-sectional surveys
[8, 9]. Finally, (iii) toxicogenomic mechanisms character-
ize diseases caused by exposure to chemical substances
that change the activity of certain genes. Two diseases
share a toxicogenomic comorbidity if they are related to
different genes that interact with the same toxic sub-
stance. For example, the immunosuppressive chemical
methoxychlor is used as pesticide and can cause atopic
dermatitis, possibly by expressing IL-13 in the skin [10].
Methoxychlor also promotes the epigenetic transgenera-
tional inheritance of kidney disease. Upon prenatal expo-
sure to methoxychlor during fetal gonadal development,
offspring show increased incidence of adult-onset kidney
disease that was related to differentially DNA methy-
lated regions [11]. Atopic dermatitis is indeed associ-
ated with the nephritic syndrome [12]. There may be
cases where the same diseases share genetic and envi-
ronmental risk factors. Such cases we regard as genetic
comorbidities, because the genetic link represents a direct
mechanism that explains a corresponding phenotypic co-
morbidity without the need for additional, environmental
influences.
The construction and analysis of networks of diseases
that are connected by different comorbidity relations has
recently lead to substantial progress in our understand-
ing of the etiologies of various diseases [2, 13, 14]. For
instance, gene-disease associations collected in the Online
Mendelian Inheritance in Man (OMIM) database [15] can
be used to construct a network where diseases are linked
if they are related to the same mutations in one or several
genes [16]. This network allowed for the identification of
clusters of diseases, such as cancers, which are held to-
gether by a small number of genes [17]. Another approach
is to connect diseases if they are both associated with en-
zymes that catalyze reactions in the same pathway [4].
Protein-protein interaction data can be integrated with
toxicogenomics data to construct a network where two
diseases are linked if they are both caused by exposure
to the same chemical, which has led to the successful
identification of novel chemical-protein associations [18].
It has recently been shown that diseases that are comor-
bid in the population tend to be related with clusters
of proteins that are close to each other in the human
protein-protein interaction network [19]. Different types
of genomic, metabolomic, and proteomic disease-disease
relations have also been combined to form an “integrated
disease network” [20, 21]. In phenotypic comorbidity net-
works, nodes correspond to disease phenotypes that are
linked if the two diseases tend to co-occur in the same
patients [22]. Chronic, multifactorial disorders often as-
sume the role of hubs in such networks (i.e. nodes that
are strongly connected with a large number of other dis-
eases) [23].
Here we construct a generalized network that combines
phenotypic comorbidity networks with those given by dif-
ferent types of shared disease-causing mechanisms (genes,
pathways, or exposure to chemicals), the human disease
multiplex network (HDMN) (see figure 2). Multiplex net-
works are given by a set of nodes connected by multiple
sets of links [24, 25]. One set of links in the HDMN corre-
sponds to phenotypic comorbidity relations, whereas the
other sets of links represent different classes of genetic
or environmental mechanisms. We quantify how simi-
lar the phenotypic links of a particular disease are to its
links in other layers in the HDMN. This allows us to de-
rive scores for each disease of how well its phenotypic co-
morbidities can be explained by genetic, pathway-based,
or toxicogenomic mechanisms. In this sense the derived
scores quantify “how genetic” or how strong environmen-
tal influences are for a given disease.
II. DATA AND METHODS
A. Data
Phenotypic disease-disease associations were obtained
from a database of the Main Association of Austrian So-
cial Security Institutions that contains pseudonymized
claims data of all persons receiving inpatient care in Aus-
tria between January 1st, 2006 and December 31st, 2007
[23, 26]. The data contains age, sex, main- and side-
diagnoses (ICD10 codes) [27] for each hospital stay from
N = 1, 862, 258 patients. Not all ICD codes represent
disorders, they may also indicate general examinations,
injuries, collections of unspecific symptoms or disorders
that are not classified elsewhere. Unspecific codes are
excluded and we work with the remaining 1, 252 diag-
noses on the three-digit ICD levels in chapters (i.e. first-
digit-levels) A-Q, labeled by the capital index I. We use
the words disease, disorder and diagnosis interchangeably
whenever referring to an ICD entry.
Molecular disease-disease associations were obtained
from molecular data of three types, namely purely ge-
netic associations and two different types of environmen-
tal associations. (i) Genetic disease associations were
extracted from the OMIM dataset [15], which provides
a collection of gene-phenotype relationships. It contains
for instance currently more than 30 genes that are known
to play a role in type 2 diabetes, e.g. the aforemen-
tioned IRS 2 gene. (ii) Pathway-based disease associ-
ations we took from the UniProtKB database [28, 29].
The UniProtKB database contains protein sequence and
functional information that is cross-referenced with path-
ways in which the proteins play a role and the protein’s
involvement in diseases. For instance, an UniProt en-
try for the PI3-kinase protein cross-references about 40
different pathways, including the PI3K/AKT activation
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FIG. 2: Illustration of the HDMN for a disease i. In the HDMN, nodes correspond to disease phenotypes that are connected
by four different types of links which can be visualized as network layers. The first layer, Mφij , encodes phenotypic comorbidity
relations. The link-weights in this layer are given by the comorbidity strengths φij that measure how often two diseases i and j
co-occur within the same patients, i.e. the numbers of patients with either disease i (red individuals) or j (blue) are compared
to the numbers of patients with both diseases (green). The second layer, MGij , contains genetic comorbidities (blue links) where
two different phenotypes (illustrated as blue and red individuals) are related to the same genetic defect or alteration. The
third type of links are pathway-based comorbidities (green links), layer MPij . Here, two different alterations occur in a pathway
that is involved in two or more different diseases. Finally, the fourth layer, MTij , is given by toxicogenomic comorbidities (red
links), where a chemical substance is known to trigger different disease-causing mechanisms. Disorder i is shown as a red node
in the HDMN, together with other phenotypes (blue nodes) that are in i’s neighborhood in at least one of the layers. The
relative comorbidity risks RRαi measure to which extent shared disease-causing mechanisms between two diseases lead to their
phenotypic comorbidity. RRαi is the average comorbidity strength of all neighbors of i in layer α, normalized to the average
comorbidity strength over all phenotypes that share no disease-causing mechanism of any type with i.
pathway, in addition to three different disease phenotypes
from the OMIM dataset. (iii) Toxicogenomic disease as-
sociations were obtained from the Comparative Toxicoge-
nomic Database (CTD) [30]. Entries in the CTD corre-
spond to chemicals that are linked to diseases caused by
exposure to the substance and with disease genes that
are differentially expressed under exposure to it. For in-
stance, according to this data the chemical methoxychlor
is involved in more than ten different diseases, includ-
ing atopic dermatitis where its influence is mediated by
eight different genes, including IL-13. To link the molec-
ular to the phenotypic data, a mapping between ICD10
and OMIM disease identifiers had to be established. To
obtain such mappings we compiled three different data
sources, namely the Human Disease Ontology database
[31], OrphaNet [32], and Wikipedia [40]. For more in-
formation on data extraction and the construction of the
ICD10-OMIM mappings see SI, Text S1. Each of the
three molecular datasets can be represented by a bipar-
tite network Bαij, where α labels the classes of mecha-
nisms, i.e. genetic (α = G), pathway-based (α = P ), or
toxicogenomic (α = T ), index i labels disorders (ICD10
codes) and j labels unique genes (if α = G), pathways
(if α = P ), or chemicals (if α = T ). We set Bαij = 1, if
there exists is at least one relation between disease i and
gene/pathway/chemical j, Bαij = 0, otherwise.
Heritability and drug approvals. Information on the
broad-sense heritability (see SI, Text S2) of individual
diseases i,H2i , was taken from the SNPedia database [33].
As a source for drug approvals we used the Drugs@FDA
database [41] from which we obtained FDA-approved
brand names and approval dates for all drug products ap-
proved since 1939. These drugs were mapped via known
molecular targets to diseases [34] to obtain the number
of newly approved drug products of the last twenty years
for the specific disease i, Di.
B. Construction of the HDMN
We constructed a multi-layer network that encodes
disease-disease associations of four different types, the
HDMN, Mαij . This network contains one phenotypic
layer, α = φ, and three layers that encode molecular
disease-disease associations, α ∈ {G,P, T }. The layer of
phenotypic disease associations,Mφij , is given by the con-
4tingency coefficient, φij , between diseases i and j: Here
Ni is the number of patients with disease i. For each pair
of diseases (i, j) we counted the number of patients that
have both diseases (Nij), only disease i or j (Nij¯ or Ni¯j ,
respectively), or neither disease (Ni¯j¯). Here, the bar de-
notes “not”. Entries in the phenotypic disease network,
Mφij , are then given by the contingency coefficient,
Mφij = φij =
NijNi¯j¯ −Nij¯Ni¯j√
NiNj(N −Ni)(N −Nj)
. (1)
Values of φij are within the range [−1,+1] and measure
the phenotypic comorbidity strength between diseases i
and j. The higher (lower) φij , the higher (lower) the
probability that a patient with disease i also suffers dis-
ease j. φij = 0 indicates that occurrences of i and j are
independent from each other. We set Mφij = 0, whenever
the patient numbers are too low to allow for a reliable
estimate of φij , i.e. whenever one of the possible out-
comes for Nij , Ni,j¯ , Ni¯,j , or Ni¯,j¯) was below 5. An age-
dependent version of the phenotypic disease network for
a given age interval t is denoted by Mφij(t). Patients fall
within one of 11 age groups, 0y-7y, 8y-15y, . . . , 80y-87y.
The layers 2, 3, and 4 of the HDMN encode three differ-
ent types of molecular associations, α ∈ {G,P, T }. Each
of these layers, Mαij , is obtained from the bipartite net-
work Bαij as follows,
Mαij =


1 if
∑
mB
α
imB
α
jm > 0
0 if α ∈ {P, T } and MGij = 1
0 otherwise
. (2)
Note that this definition ensures that associations be-
tween pathologies i and j in the pathway, MPij , and tox-
icogenomic, MTij , layers are indeed due to shared path-
ways or exposure to the same chemical that can not be
explained by direct genetic causes (i.e. MGij = 1).
The numbers of non-isolated nodes, Nα, and links, Lα,
for each layer α are shown in the SI, table SI. Diseases are
not included in the HDMN if they are isolated in every
molecular layer α = G,P , or T . Links in the phenotypic
layer Mφ are weighted and typically close to zero [22,
23]. Numbers for Nα are between 200 and 300 for the
molecular layers, whereas there are more than 350 nodes
in the phenotypic layer.
C. Disease risks from shared pathophysiological
mechanisms
We introduce a relative risk indicator RRαi that mea-
sures how similar the phenotypic comorbidities of disease
i are to its genetic, pathway-based, or toxicogenomic co-
morbidities. In this sense RRαi quantifies how much a
specific class of disease-causing mechanisms contributes
to the phenotype i. RRαi is the quotient of the average
comorbidity strengths,Mφij , of all diseases that are linked
to i in layer Mαij , and the comorbidity strengths of those
diseases that are linked to i in none of the pathophysio-
logical layers, i.e.,
RRαi =
1
kα
i
∑
jM
φ
ijM
α
ij
1
|LC
i
|
∑
jM
φ
ij
. (3)
Here kαi is the degree of disease i in layer α given by
kαi =
∑
jM
α
ij and L
C
i is a control set of links for dis-
ease i that contains all links j, i 6= j, for which ∀α ∈
{G,P, T } : Mαij = 0. For convenience we also defined
the logarithmic relative comorbidity risk, rαi = logRR
α
i .
A value of rαi close to zero indicates that the presence of
pathophysiological comorbidities of type α have no rela-
tion whatsoever to the actual, phenotypic comorbidities
of i. With increasingly positive values of rαi , the proba-
bility increases that the pathophysiological comorbidities
of i are indeed observed in the population.
Note that the relative comorbidity risk rαi can be large
due to a single comorbidity j of type α with a very high
phenotypic comorbidity strength Mφij , or because there
are a large number of comorbidities with only moderately
increased comorbidity strengths. In particular, rαi might
favor diseases that have a large number of connections of
type α to diseases that are physiologically very similar
and that have similar ICD10 diagnosis codes, see Text
S1. To adjust for these biases we rescaled rαi by the
node degree kαi to obtain a measure that favors diseases
with a smaller number of highly relevant disease-causing
mechanisms. The re-scaled comorbidity risk, qαi , is given
by qαi =
rα
i
kα
i
.
We performed two different statistical tests to evalu-
ate whether rαi is significantly greater than zero. First, a
Wilcoxon rank sum test for equal medians of two samples
was performed. The samples were given by the set of co-
morbidity strengthsMφij of all diseases j that share a link
of type α with i, S1 = {M
φ
ij|∃j : M
α
ij = 1}, and the set
S2 = {M
φ
ij|j ∈ L
C
i }. The p-value for r
α
i , p
α
i , was obtained
from the one-sided Wilcoxon rank sum test against the
alternative hypothesis that the median of S1 is smaller
than the median of S2. A Benjamini-Hochberg multiple
hypothesis testing correction was applied on each layer
using an exploratory threshold for the false discovery rate
of α = 0.25 (which corresponds to thresholds for the ad-
justed p-values in the range between 0.1 and 0.05). Sec-
ond, we performed a randomization test for rαi where we
replace Mαij by a random permutation of its elements,
denoted by M˜αij . The randomized r˜
α
i was computed from
equation 3 where Mαij was replaced by M˜
α
ij . For a given
α, M˜αij has the same number of nodes and links as M
α
ij ,
but is otherwise completely randomized.
III. RESULTS AND DISCUSSION
The estimates of the most probable disease causes can
be visualized in a three-dimensional representation where
5the axes show the genetic, pathway-based, and toxicoge-
nomic comorbidity risks. Each disease corresponds to a
point with coordinates (rGi , r
P
i , r
T
i ), see figure 3(a) and
its projections onto the (b) G − P , (c) G − T , and (d)
P − T planes. The size of each marker is proportional
to the frequency Ni/N of disease i. We set r
α
i = 0
for all diseases where rαi is not significantly different
from zero after the multiple hypothesis testing correc-
tion. The majority of disorders are clearly dominated by
genetic risk factors (many points are close to the G-axis).
Some disorders cluster around the P and T axes indi-
cating purely pathway-based and toxicogenomic origins.
Intriguingly, there is precisely no disease that has a signif-
icant pathway-based and toxicogenomic comorbidity risk
at the same time, see figure 3(d). However, a number
of disorders with significant pathway-based or toxicoge-
nomic risks have also significant genetic contributions,
see figures 4(b) and (c). This can also be seen in table I,
where for instance the chronic nephritic syndrome ranks
high in genetic and toxicogenomic comorbidity risks.
The per-link contributions, qαi , of three types of patho-
physiological mechanisms are shown in figures 3(e)-(h).
Almost all disorders show one dominant comorbidity
risk contribution, i.e. they cluster around a single axis.
Again, most diseases show large genetic risks, while some
cluster around the P and T axes. In the supporting in-
formation, SI Figure 2, we show results for qαi where we
allow comorbidities that are at the same time genetic and
pathway-based/toxicogenomic (i.e. we drop the second
condition for Mαij in equation 2). There are now disor-
ders with, both, significant pathway-based and toxicoge-
nomic comorbidity risks. For these comorbidities, how-
ever, there exists also a direct genetic mechanism that
may account for the phenotypic comorbidities.
Table I shows the diseases with the largest ge-
netic, pathway-based, or toxicogenomic comorbidity
risks, ranked by statistical significance. The top genetic
diseases include schizo-affective and delusional disorders,
as well as schizophrenia. Different forms of osteoarthritis
and chronic bronchitis, as well as nephrotic and nephritic
syndromes also show high genetic comorbidity risks. The
top pathway-based diseases are major depressive disor-
ders, endocrine disorders such as obesity and amyloido-
sis, diseases of the nervous systems including epilepsy
and extrapyramidal and movement disorders, as well as
disorders of bone density and multiple myeloma. The
top toxicogenomic diseases include various forms of der-
matitis and other skin diseases such as lichen simplex
chronicus and prurigo, but also aortic aneurysms, and
the chronic nephritic syndrome.
Schizophrenia is indeed a highly heritable disorder that
is associated with more than hundred gene loci [35]. The
large pathway-based risk for depressions is corroborated
by strong and supposedly bi-directional associations be-
tween the metabolic syndrome and depression, which
have been a long-standing puzzle in epidemiological stud-
ies [36]. Depressions also exhibit strongly significant ge-
netic comorbidity risks (rGi = 2.3, p
G
i < 0.01) in consis-
TABLE I: Top 10 diseases in every class of disease-causing
mechanisms, α, and their relative comorbidity risks rαi ,
ranked by the significance of its overlap with the phenotypic
disease layer, pαi .
rank genetic, α = G rαi p
α
i
1 F25, Schizo-affective disorders 2.4 < 10−4
2 F20, Schizophrenia 2.4 < 10−4
3 M19, Osteoarthritis (unspecified) 2.9 < 10−4
4 N04, Nephrotic syndrome 2.2 < 10−4
5 J41, Simple, mucopurulent chronic
bronchitis
2.1 < 10−3
6 J42, Chronic bronchitis (unspecified) 2.0 < 10−3
7 M15, Polyosteoarthritis 2.6 < 10−3
8 N03, Chronic nephritic syndrome 2.3 < 10−3
9 F22, Delusional disorders 2.6 < 10−3
10 M18, Osteoarthritis (first carpometacarpal
joint)
2.5 < 10−3
pathway-based, α = P
1 F32, Major depressive disorder, single
episode
1.1 < 10−3
2 F33, Major depressive disorder, recurrent 0.81 0.002
3 M85, Disorders of bone density and
structure
1.8 0.003
4 G40, Epilepsy and recurrent seizures 0.65 0.003
5 E66, Overweight and obesity 0.83 0.006
6 E85, Amyloidosis 0.58 0.009
7 G25, Other extrapyramidal and movement
disorders
0.66 0.010
8 H90, Conductive and sensorineural hearing
loss
0.56 0.010
9 M21, Other acquired deformities of limbs 1.3 0.010
10 C90, Multiple myeloma, plasma cell
neoplasms
0.90 0.011
toxicogenomic, α = T
1 I71, Aortic aneurysm and dissection 0.75 0.002
2 L21, Seborrheic dermatitis 0.65 0.002
3 L24, Irritant contact dermatitis 0.99 0.002
4 K52, Gastroenteritis and colitis 0.64 0.002
5 N03, Chronic nephritic syndrome 1.7 0.004
6 L20, Atopic dermatitis 1.2 0.004
7 L28, Lichen simplex chronicus and prurigo 0.69 0.006
8 L30, Unspecified dermatitis 0.58 0.006
9 I89, Noninfective disorders of lymphatic
vessels and nodes
0.84 0.008
10 G91, Hydrocephalus 0.96 0.009
tency with the finding of a gene-by-environment interac-
tion where individuals with a functional polymorphism
in the promoter region of the serotonin transporter (5-
HT T) gene exhibited more depressive symptoms in rela-
tion to stressful life events [37]. The high toxicogenomic
risks for aortic aneurysms are in line with the effects of
chemicals such as nicotine and prostaglandin on related
disease-genes [38].
Since phenotypic disease networks are known to un-
dergo large changes in their topology as a function of
the age of the underlying patient cohorts [23], we first
clarified how the relative comorbidity risks rαi depend
on patient age. The age-dependent relative risks, rαi (t),
were computed using equation 3 and by replacing Mφij
6FIG. 3: Classification of diseases (circles) according to the dominant causes of their phenotypic comorbidities. Results are
shown for (a-d) the relative comorbidity risks rαi and (e-h) their re-scaled versions, q
α
i . Circle size is proportional to the number
of disease occurrences. Re-scaling the risks by the degrees leads to almost perfect clustering of the diseases around one of
the axes. The per-link contribution to the relative comorbidity risk is always dominated by one specific mechanism. Only a
comparably small number of diseases cluster around the toxicogenomic axis. The comorbidity risks for most pathologies are
dominated by genetic disease-causing mechanisms.
with its age-dependent counterpart, Mφij(t). Results for
the average relative comorbidity risks over all diseases i,
denoted by 〈rαi (t)〉i, are shown in figure 4(a). Note that
this average is also taken over diseases with comorbidity
risks rαi (t) that are not significantly different from zero.
The genetic comorbidity risk averaged over all diseases
i, 〈rGi (t)〉i, is substantially higher than the pathway-
based or toxicogenomic risks and assumes values above
1 for ages between 30 and 90. Effects are considerably
smaller for the average pathway-based (toxicogenomic)
comorbidity risks that reach values around 0.5 at ages
around 30 (50). These age differences in the peaks of
the environmental comorbidity risks are driven by the
age-dependence in the prevalences of the diseases that
provide the most dominant contributions to 〈r
P (T )
i (t)〉i.
In all cases, results for 〈rαi (t)〉i clearly exceed the ex-
pectation values from the randomized risks 〈r˜αi (t)〉i, ob-
tained from M˜αij . Note that we have confirmed that the
dominance of genetic disorders can not be a simple con-
sequence of the exclusion of genetic comorbidities in the
other molecular layers in equation 2. Removing this con-
straint would increase the average environmental contri-
butions by a factor of about 1.5, while the genetic co-
morbidity risks exceed them by a factor between four and
five. From now on we consider only the time-independent
HDMN.
Figure 4(b) shows how much genetic, pathway-based,
and toxicogenomic risks contribute to the observed co-
morbidities for subgroups of diseases that are given by
the chapters of the ICD10 classification, the disease
groups I. Clear differences between groups of diseases
are revealed. Genetically caused comorbidities include
mental disorders, disorders of the digestive system, but
also susceptibility to infections. Genetic mechanisms are
least relevant for disorders of the eye, ear, skin, and for
cancers. Pathway-based comorbidity risks are largest for,
again, mental disorders and diseases of the genitourinary
system. This shows that the group of mental disorders
comprises heterogeneous phenotypes that have either ge-
netically caused or pathway-based comorbidities. Tox-
icogenomic comorbidity risks are largest for diseases of
the skin, the genitourinary and the respiratory system,
as well as for congenital malformations.
The “nurture index”, Ii, quantifies to which extent co-
morbidities of phenotype i are caused by environmental,
i.e. pathway-based or toxicogenomic, mechanisms,
Ii =
√
(qPi )
2 + (qTi )
2 . (4)
Figure 5 shows results for (a) the heritability and (b)
the number of new drug approvals Di as a function of
Ii. Each circle in figure 5 corresponds to a disease phe-
notype, labeled by its ICD10 code. The colors of the
circles refer to their chapter in the ICD classification.
The highest values of Ii are found for diseases of the gen-
itourinary system (N03 and N05 nephritic syndrome, N02
hematuria, N08 glomerular disorders), depressions (F32,
F33), several cancers (C84 T/NK-cell lymphoma, C74
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FIG. 4: Contributions of genetic, pathway-based, and toxicogenomic comorbidity risks. (a) The genetic risks, rGi (t), clearly
exceed the pathway-based, rPi (t), and toxicogenomic, r
T
i (t), risks across all ages of patients. The results for all three types of
mechanisms exceed their expectations from the randomization test (markers connected by dotted lines, error bars show the
standard deviation over 5,000 randomizations). (b) Averages of the relative risks are shown for the chapters of the ICD10
classification, the solid vertical lines show the values of genetic (blue), pathway-based (green) and toxicogenomic (red) risks
averaged over all diseases. Diseases of the digestive system, mental disorders, and infections show the highest genetically caused
comorbidity risk, whereas cancers, diseases of the skin, eye, and ear show the lowest genetic risks. Pathway-based contributions
are also highest for mental disorders and toxicogenomic contributions assume their maximum for diseases of the genitourinary
system.
adrenal gland, C61 prostate), as well as bronchiectasis
(J47). Figure 5(a) shows that there is a significant neg-
ative correlation between the nurture index, Ii, and the
broad-sense heritability, H2i , of disorder i. This corrobo-
rates that Ii is indeed related to the plasticity of pheno-
type i, i.e. Ii increases with the influence of environmen-
tal risk factors. There is also a strong significant negative
correlation between the logarithms of Ii and Di shown in
figure 5(b). We found this result to be very robust for
a large variety of choices of this time span, ranging from
five years upwards. Note that logDi and H
2
i show no
significant correlation among them (ρ = 0.19, p = 0.17).
This indicates a significant bias in pharmaceutical R&D
that favors market placements of drugs that target dis-
orders with low environmental risk factors. It has indeed
been shown that the success rates for drug development
vary dramatically among disease areas [39]. These rates
have been found to increase with the existence of direct
genetic evidence, which in particular applies to diseases
of the musculoskeletal system and infections, which we
also identified as predominantly genetic in figure 3(b).
IV. CONCLUSIONS
We developed a novel approach to quantitatively dis-
entangle the most relevant genetic or environmental
disease-causing mechanisms for a large number of partic-
ular disorders. This has become possible through recent
advances in observing networks of phenotypic comorbid-
ity relations with unprecedented precision [22, 23]. We
considered three different classes of mechanisms that can
be at the core of these observed comorbidities, namely
genetic, pathway-based, and toxicogenomic mechanisms
that cause more than one disorder. By constructing the
HDMN we have been able to identify the most proba-
ble causes for 358 different phenotypes by measuring the
overlap between phenotypic and pathophysiological co-
morbidities, the relative comorbidity risks rαi . We find
that the different environmental disease-causing mecha-
nisms do not mix; we found no pathologies that have
significant pathway-based and toxicogenomic comorbid-
ity risk contributions at the same time. While for most
of the studied diseases genetic risk factors dominate, we
identify a number of disorders with significant environ-
mental contributions which typically coincides with low
heritability and lower rates of successful market place-
ments of drugs.
Our approach cross-validates pathophysiological mech-
anisms by whether their predicted comorbidities are in-
deed directly observed in the population. Moreover we
can rule out certain types of disease-causing mechanisms
when the comorbidities that they predict are not ob-
served. The methodology developed here can be ex-
tended to decide on a quantitative basis if the comor-
bidities predicted by a particular individual pathophysi-
ological mechanism are also phenotypically relevant. The
new technology can be used as a novel and data-driven
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FIG. 5: Heritability H2i , (a) and the number of newly devel-
oped drugsDi (b) are negatively correlated with the relevance
of environmental risk factors for diseases. Each circle corre-
sponds to one disease phenotype, labeled by its three-digit
ICD10 code. Both, H2i and Di are shown as a function of
the nurture index. Colors indicate the main ICD chapter to
which the diseases belong. We observe particularly high Ii
values for diseases of the genitourinary system, various can-
cers, depression, and bronchiectasis.
way to validate potential drug targets.
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V. SUPPLEMENTARY INFORMATION
A. Text S1: Further details on data extraction and
MIM-ICD10 mappings
Genetic disease associations are extracted from the
Online Mendelian Inheritance in Man (OMIM) dataset,
from which we obtained a list of 4,847 associations be-
tween disorders (phenotype MIM numbers) and genes
[15]. Thereby we included only those phenotype-gene
associations for which the molecular basis of the disorder
is known (i.e. a phenotype mapping key with value 3 in
the OMIM dataset). Metabolic disease associations stem
from the UniProtKB database, which provides a list of
3,020 proteins that are known to be involved in disor-
ders in humans (given by phenotype MIM numbers) [28].
The REACTOME database cross-references these pro-
teins with pathways in which they occur [29]. Toxicoge-
nomic disease associations are obtained from the Com-
parative Toxicogenomic Database as a list of 4,925 asso-
ciations between disorders (phenotype MIM numbers or
MeSH ID) and chemicals [30]. Here we only use curated
disease-chemical associations, i.e. those for which direct,
literature-curated evidence exists.
To obtain mappings from MIM phenotype num-
bers and MeSH codes to the ICD10 classification
we compile three different data sources. In addi-
tion to the Human Disease Ontology database [31]
and mappings provided from OrphaNet [32], we ex-
tracted mappings by crawling a disease index page
from Wikipedia (https://en.wikipedia.org/wiki/ICD-10,
retrieved 04/30/2015). From these three sources result
85,303 MeSH-ICD10 and 5,498 MIM-ICD10 associations.
Aggregated to the three-digit ICD10 level, 90% of the
ICD10 codes can be mapped to MeSH codes and 37% to
MIM numbers. This lower number of successfully trans-
lated MIM numbers is partly due to the fact that not for
all diseases a molecular basis is known or even relevant.
While the ICD10 codes are primarily used for billing
and clinical purposes, the OMIM classification focuses
on descriptive phenotypes of inherited conditions. From
this follows the limitation that some very specific OMIM
codes might link to highly unspecific ICD10 codes and
vice versa. For instance, colorectal cancer has one MIM
number (114500) but four different ICD10 codes on the
three-digit level, C18-C21. These four phenotypes are
not only connected among each other; each disease that
is genetically linked to colorectal cancer is also linked to
all four of these ICD10 codes. Consequently the diag-
noses C18-C21 have the highest degrees in the genetic
comorbidity network. Similarly, the ICD10 codes for es-
sential hypertension (I10-I13) all map to a single MIM
number and have the highest degrees in the toxicoge-
nomic disease network. We therefore adjusted for such
biases by re-scaling the relative comorbidity risk rαi by
the node degree kαi .
TABLE I: Overview of characteristics of the HDMN layers.
The numbers of non-isolated nodes, Nα, and links, Lα, are
given for four different layers.
α Nα Lα
phenotypic 358 63903
genetic 285 969
pathway-based 251 3930
toxicogenomic 199 4994
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FIG. 1: Classification of diseases (circles) according to the
dominant contributions to their phenotypic comorbidities for
an alternative definition of the re-scaled relative comorbidity
risks, qαi , where two diseases can at the same be comorbid in
a genetic of pathway-based / toxicogenomic way. Again, most
diseases cluster around one of the axis with a clear dominance
of genetic comorbidity risks.
B. Text S2: Broad-sense heritability
Heritability is a measure that quantifies how much
variation in a phenotypic trait (such as a disease) in a
population is due to genetic variation among individu-
als in the population. More specifically, if σG is the ge-
netic variation and σP the variation in the population,
the broad-sense heritability, H2, is defined as H2 = σG
σP
.
Sloppily defined, heritability measures the proportion of
(disease) risk that is due to the genetic background of an
individual, as opposed to environmental factors. How-
ever, high values of heritability do not necessarily imply
a high disease risk, as it may be relatively easy to prevent
certain genetic diseases by certain interventions.
